Attovia Therapeutics, Inc.
No enriched coverage for $ATTO in the last 7 days.
Attovia Therapeutics (NASDAQ:ATTO) began trading after an IPO, with shares around $19.86 and a market cap near $287.9 million. The company’s pipeline targets IL-31 itch via ATTO-1310 in Phase 1, plus ATTO-2306 (IND-enabling, Phase 1 expected H1 2027) and ATTO-1091. Attovia raised about $255.8 million as of March 31, 2026.
WALSH COLIN sold 105,807 indirectly-held shares of Attovia Therapeutics, Inc. (ATTO) at an average of $21.28 ($20.84–$22.19, $2.25M total) across 23 trades on 2026-08-05.
WALSH COLIN purchased 585,000 indirectly-held shares of Attovia Therapeutics, Inc. (ATTO) at an average of $17.58 ($17.00–$21.00, $10.28M total) across 2 trades over 2026-08-05 to 2026-08-06.
Recent ATTO coverage spans insider activity, ipo and financial news.
In the last 30 days, ATTO insiders filed 55 SEC Form 4 transactions — 9 purchases ($52.4M) and 46 sales ($4.5M). The most active reporter was GOLDMAN SACHS GROUP INC with 25 filings.
Near-term trading is driven by early IPO price action and the long gap to first meaningful clinical readouts, making sentiment and dilution risk key.
This is a routine insider sale with no stated 10b5-1 plan, but it does not disclose new company fundamentals.
The filing is a fresh insider purchase signal, but it is not tied to new fundamentals or guidance in the text.
The filing signals a complete exit by the reporting group from ATTO via indirect holdings, which can affect near-term sentiment but not fundamentals by itself.
This is an insider-style Form 4 disclosure for ATTO, but it is an indirect purchase by a large financial firm, not a company action or fundamental update.
alphai scores every news story that mentions ATTO with an AI model for sentiment and relevance, and aggregates insider trades from Attovia Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Attovia Therapeutics (NASDAQ:ATTO) began trading after an IPO, with shares around $19.86 and a market cap near $287.9 million. The company’s pipeline targets IL-31 itch via ATTO-1310 in Phase 1, plus ATTO-2306 (IND-enabling, Phase 1 expected H1 2027) and ATTO-1091. Attovia raised about $255.8 million as of March 31, 2026.
6 min readWALSH COLIN sold 105,807 indirectly-held shares of Attovia Therapeutics, Inc. (ATTO) at an average of $21.28 ($20.84–$22.19, $2.25M total) across 23 trades on 2026-08-05.
2 min readWALSH COLIN purchased 585,000 indirectly-held shares of Attovia Therapeutics, Inc. (ATTO) at an average of $17.58 ($17.00–$21.00, $10.28M total) across 2 trades over 2026-08-05 to 2026-08-06.
1 min readGOLDMAN SACHS GROUP INC sold 105,807 indirectly-held shares of Attovia Therapeutics, Inc. (ATTO) at an average of $21.28 ($20.84–$22.19, $2.25M total) across 23 trades on 2026-08-05. Filed jointly with GOLDMAN SACHS & CO. LLC, GOLDMAN SACHS ASSET MANAGEMENT, L.P., Broad Street Principal Investments, L.L.C., WSLS OFFSHORE INVESTMENTS, SLP, West Street Life Sciences I, L.P., WSLS EMP OFFSHORE INVESTMENTS, L.P. and WSLS EMP ONSHORE INVESTMENTS, L.P..
2 min readGOLDMAN SACHS GROUP INC purchased 585,000 indirectly-held shares of Attovia Therapeutics, Inc. (ATTO) at an average of $17.58 ($17.00–$21.00, $10.28M total) across 2 trades over 2026-08-05 to 2026-08-06. Filed jointly with GOLDMAN SACHS & CO. LLC, GOLDMAN SACHS ASSET MANAGEMENT, L.P., Broad Street Principal Investments, L.L.C., WSLS OFFSHORE INVESTMENTS, SLP, West Street Life Sciences I, L.P., WSLS EMP OFFSHORE INVESTMENTS, L.P. and WSLS EMP ONSHORE INVESTMENTS, L.P..
1 min readDeep Track Capital and affiliates filed a Schedule 13G for Attovia Therapeutics, Inc. (ATTO), disclosing beneficial ownership of 3,207,138 shares, or 7.45% of the outstanding common stock. The group reports shared voting and dispositive power over all shares, with calculations based on 43,029,017 shares outstanding as of Aug. 5, 2026, per Attovia’s prospectus.
2 min readvenBio Global Strategic Fund IV, L.P. purchased 382,352 shares of Attovia Therapeutics, Inc. (ATTO) at $17.00 ($6.50M total) on 2026-08-06.
1 min readAttovia Therapeutics (ATTO) SEC filings describe IPO-related conversions and insider/option activity. On Aug 6, 2026, Series A-1, A-2, B and C preferred converted to common on a 9.29:1 basis, and 782,854 Series B preferred converted into common. Redmile vehicles bought 600,000 shares at $17.00. Multiple directors and executives received stock options with $17.00 exercise price and 2027-2036 vesting.
4 min readRedmile Group, LLC purchased 400,000 indirectly-held shares of Attovia Therapeutics, Inc. (ATTO) at $17.00 ($6.80M total) on 2026-08-06.
2 min readRedmile Group, LLC purchased 200,000 shares of Attovia Therapeutics, Inc. (ATTO) at $17.00 ($3.40M total) on 2026-08-06.
2 min read
